+ +

•  

   

     Western blot analysis of Retinoic Acid Receptor beta expression in MCF7 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

The retinoic acid receptor beta (RARβ) is a nuclear receptor that plays a critical role in mediating the effects of retinoic acid (RA), a metabolite of vitamin A essential for cell differentiation, proliferation, and apoptosis. As part of the RAR subfamily (RARα, β, γ), RARβ binds to RA and forms heterodimers with retinoid X receptors (RXRs) to regulate the transcription of target genes by interacting with specific RA response elements (RAREs) in DNA. RARβ is particularly notable for its tumor-suppressive functions, as its expression is frequently downregulated in various cancers due to promoter hypermethylation or epigenetic silencing, making it a biomarker of interest in oncology research.

Antibodies targeting RARβ are vital tools for studying its expression, localization, and functional roles in both normal and pathological conditions. These antibodies enable techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to investigate RARβ protein levels, tissue distribution, and DNA-binding activity. Researchers also use RARβ antibodies to explore its involvement in developmental processes, cellular responses to RA therapy, and mechanisms underlying chemoprevention or resistance in cancers. Specific isoforms (e.g., RARβ1. β2. β4) may be distinguished using isoform-selective antibodies, aiding in dissecting their distinct biological roles. Validation of RARβ antibodies for specificity and cross-reactivity is crucial, given the structural similarities among nuclear receptor family members.